Skip to main content

Table 1 Demographic and clinical data

From: Long-term implications of structured transition of adolescents with inflammatory bowel disease into adult health care: a retrospective study

 

Transfer (n = 11)

Transition (n = 24)

p-value

Gender male (M) / female (F), n (%)

M = 7 (64%)

F = 4 (36%)

M = 14 (58%)

F = 10 (42%)

1.000*

Diagnosis, n (%)

  

0.279+

 CD

8 (73%)

12 (50%)

 

 UC

2 (18%)

11 (46%)

 

 IBDU

1 (9%)

1 (4%)

 

Age at diagnosis in years

14 (±2)

14 (±3)

0.754^

Paris classification [20] of CD patients

 Age of onset, n (%)

  

0.209+

  A1a

1 (12%)

0 (0%)

 

  A1b

10 (88%)

12 (100%)

 

 Location of disease, n (%)

  

0.082+

  L1

2 (25%)

0 (0%)

 

  L2

0 (0%)

3 (25%)

 

  L3

6 (75%)

9 (75%)

 

 Upper gastrointestinal inflammation, n (%)

  

0.690+

  L4a

4 (50%)

6 (50%)

 

  L4b

0 (0%)

1 (8%)

 

 Behaviour of disease at diagnosis, n (%)

  

0.402+

  B1

8 (100%)

11 (92%)

 

  B2

0 (0%)

0 (0%)

 

  B3

0 (0%)

0 (0%)

 

  B2B3

0 (0%)

1 (8%)

 

 Perianal disease

3 (38%)

5 (42%)

1.000*

 Growth

  

0.111+

  G0

4 (50%)

10 (83%)

 

  G1

4 (50%)

2 (17%)

 

Paris classification of UC patients

 Extension of inflammation, n (%)

  

0.701+

  E1

0 (0%)

1 (9%)

 

  E2

0 (0%)

2 (18%)

 

  E3

0 (0%)

0 (0%)

 

  E4

2 (100%)

8 (73%)

 

 Disease severity, n (%)

  

0.140+

  S0

1 (50%)

10 (91%)

 

  S1

1 (50%)

1 (9%)

 

Total duration of follow-up in paediatric care in years (range)

5 (2–11)

3 (2–10)

0.303#

Age at transfer in years (range)

20 (18–22)

18 (17–21)

0.082#

Total duration of follow-up in adult care in years (range)

2 (2–8)

2 (2–5)

0.394#

Prevalence of previous and current EIM, n (%)

7 (64%)

13 (54%)

0.721*

Medical treatment before study period (at least used once), n (%)

 Thiopurines

11 (100%)

22 (92%)

1.000*

 5-ASA

8 (73%)

18 (75%)

1.000*

 Steroids

6 (55%)

16 (67%)

0.708*

 EEN

3 (27%)

6 (25%)

1.000*

 Biologicals

3 (27%)

5 (21%)

0.685*

Medical treatment within the study period (at least used once), n (%)

 Thiopurines

11 (100%)

22 (92%)

1.000*

 5-ASA

8 (73%)

18 (75%)

1.000*

 Steroids

8 (73%)

18 (75%)

1.000*

 EEN

4 (36%)

6 (25%)

0.689*

 Biologicals

5 (46%)

7 (29%)

0.451*

  1. Legend. CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; IBDU, unclassified IBD; A1a, 0–< 10 years; A1b, 10–< 17 years; B1, non-stricturing-non-penetrating disease; B2, stricturing disease; B3, penetrating disease; B2B3, both penetrating and stricturing disease; G0, no growth failure; G1, evidence of growth delay [G1]; L1, distal 1/3 ileal disease (limited cecal disease); L2, colonic disease; L3, ileo-colonic disease; L4, upper gastrointestinal tract disease; L4a, esophago-gastro-duodenal disease proximal to ligament of Treitz; L4b, distal to ligament of Treitz; E1, ulcerative proctitis; E2, left-sided ulcerative colitis (distal to splenic flexure); E3, extensive colitis (hepatic flexure distally); E4, pancolitis (proximal to hepatic flexure); S0, not severe; S1, ever severe; extraintestinal manifestations, EIM; 5-ASA, 5-aminosalicylic acids; EEN, exclusive enteral nutrition; *Fisher’s exact test; +Chi-square test; #Mann-Whitney U test; ^2-sample t test
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us